Genmab's EPKINLY Combination Approved by FDA for Relapsed Follicular Lymphoma

Key highlights
  • EPKINLY + R² reduced disease progression risk by 79% in Phase 3 trial.
  • Median progression-free survival was not reached for EPKINLY + R².
  • 89% of patients responded to EPKINLY + R², with 74% achieving complete response.
  • Common adverse reactions included rash, infections, and fatigue.

FDA Approval

The U.S. FDA has approved EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R²) for adult patients with relapsed or refractory follicular lymphoma. This marks the first bispecific-based therapy approved for this condition in the second-line setting.

Phase 3 Trial Results

The approval is based on the Phase 3 EPCORE FL-1 study, where EPKINLY + R² demonstrated a 79% reduction in the risk of disease progression or death compared to the standard R² treatment. The median progression-free survival was not reached for EPKINLY + R², while it was 11.2 months for R².

Response Rates

In the trial, 89% of patients responded to EPKINLY + R², with 74% achieving a complete response. This is compared to a 74% overall response rate and 43% complete response rate for those treated with R².

Safety Profile

The safety profile of EPKINLY + R² was consistent with known profiles of the individual regimens. Common adverse reactions included rash, upper respiratory tract infections, fatigue, and injection site reactions. Cytokine release syndrome occurred in 24% of patients, primarily low grade, and one case of immune effector cell-associated neurotoxicity syndrome was reported.

Source: Genmab

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

5 November 2026
Genmab nine-month 2026 results: revenue up 22%, epcoritamab approved, Phase‑3 readouts positive

Revenue rose 22% to $3,238m; epcoritamab approved in Europe and Japan; two Phase‑3 starts for petosemtamab in CRC; multiple Phase‑3 topline readouts were positive.

5 October 2026
Genmab and AbbVie: Epcoritamab + R‑CHOP cuts progression risk 51% in frontline DLBCL Phase 3

Phase 3 trial of subcutaneous T‑cell‑engaging bispecific with R‑CHOP cut progression/death risk by 51% in newly diagnosed DLBCL (IPI 2–5); safety consistent with known profiles.

23 July 2026
Genmab and AbbVie clarify EPCORE DLBCL-1 US primary endpoint not met

The trial's sole U.S. primary endpoint—overall survival—did not reach statistical significance; additional results will be submitted for peer review.

6 July 2026
Genmab: EC approves TEPKINLY (epcoritamab) + lenalidomide and rituximab for relapsed/refractory follicular lymphoma

First bispecific‑based, chemotherapy‑free second‑line option in Europe after Phase 3 showed major PFS benefit and high complete response rates.

29 June 2026
Genmab: EPCORE DLBCL-4 shows PFS benefit for epcoritamab plus lenalidomide

Phase 3 topline: fixed‑duration subcutaneous epcoritamab + lenalidomide significantly reduced progression/death versus R‑GemOx in relapsed/refractory DLBCL; safety consistent with known profiles.